Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher
In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).
In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”
Johnson & Johnson closed on Friday at $103.73.
Latest Ratings for JNJ
|May 2016||Standpoint Research||Initiates Coverage on||Sell|
|May 2016||BTIG Research||Downgrades||Buy||Neutral|
|May 2016||Credit Suisse||Maintains||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.